JNJ · Johnson & Johnson - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $94.94B | $93.78B | $82.58B |
| Cost of Revenue | $30.26B | $27.47B | $26.55B | $31.09B | $29.86B | $28.43B |
| Gross Profit | $63.94B | $61.35B | $58.61B | $63.85B | $63.92B | $54.16B |
| R&D | $109.00M | $1.84B | $0 | $14.60B | $14.71B | $12.16B |
| SG&A | $23.68B | $22.87B | $21.51B | $24.77B | $24.66B | $22.08B |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $7.50B | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B |
| Operating Income | $32.58B | $16.69B | $15.06B | $21.73B | $16.50B | $16.50B |
| Interest Expense | $971.00M | $276.00M | $772.00M | $276.00M | $183.00M | $201.00M |
| Income Tax | $5.78B | $2.62B | $1.74B | $3.78B | $1.90B | $1.78B |
| Net Income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B |
| EPS - Basic | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 |
| EPS - Diluted | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.71B | $24.11B | $21.86B | $14.13B | $14.49B | $13.98B |
| Accounts Receivable | $17.18B | $14.84B | $14.87B | $16.16B | $15.28B | $13.58B |
| Inventory | $14.19B | $12.44B | $11.18B | $12.48B | $10.39B | $9.34B |
| Accounts Payable | $11.99B | $10.31B | $9.63B | $11.70B | $11.05B | $9.51B |
| Current Assets | $55.62B | $55.89B | $53.49B | $55.29B | $60.98B | $51.24B |
| Total Assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B |
| Current Liabilities | $54.13B | $50.32B | $46.28B | $55.80B | $45.23B | $42.49B |
| Long-term Debt | $39.44B | $30.65B | $25.88B | $26.89B | $29.98B | $32.63B |
| Total Liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B | $111.62B |
| Stockholders' Equity | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B |
| Retained Earnings | $168.98B | $155.79B | $153.84B | $128.34B | $123.06B | $113.89B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B | $23.54B |
| Investing Cash Flow | ($23.59B) | ($18.60B) | $878.00M | ($12.37B) | ($8.68B) | ($20.82B) |
| Financing Cash Flow | ($5.54B) | ($3.13B) | ($15.82B) | ($8.87B) | ($14.05B) | ($6.12B) |
| CapEx | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B | $3.35B |
| Free Cash Flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B | $20.19B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 67.9% | 69.1% | 68.8% | 67.3% | 68.2% | 65.6% |
| Operating margin | 34.6% | 18.8% | 17.7% | 22.9% | 17.6% | 20.0% |
| EBITDA margin | 42.6% | 27.0% | 26.5% | 30.2% | 25.5% | 28.7% |
| Net margin | 28.5% | 15.8% | 41.3% | 18.9% | 22.3% | 17.8% |
| Free cash flow margin | 20.9% | 22.3% | 21.4% | 18.1% | 21.1% | 24.4% |
| FCF / Net income | 0.73 | 1.41 | 0.52 | 0.96 | 0.95 | 1.37 |
| R&D / Revenue | 0.1% | 2.1% | 0.0% | 15.4% | 15.7% | 14.7% |
| SG&A / Revenue | 25.1% | 25.7% | 25.3% | 26.1% | 26.3% | 26.7% |
| Effective tax rate | 17.7% | 15.7% | 4.7% | 17.4% | 8.3% | 10.8% |
| Return on assets | 13.5% | 7.8% | 21.0% | 9.6% | 11.5% | 8.4% |
| Return on equity | 32.9% | 19.7% | 51.1% | 23.4% | 28.2% | 23.3% |
| Return on invested capital | 22.2% | 13.8% | 15.2% | 17.3% | 14.5% | 15.3% |
| Liquidity | ||||||
| Current ratio | 1.03 | 1.11 | 1.16 | 0.99 | 1.35 | 1.21 |
| Quick ratio | 0.77 | 0.86 | 0.91 | 0.77 | 1.12 | 0.99 |
| Cash ratio | 0.36 | 0.48 | 0.47 | 0.25 | 0.32 | 0.33 |
| Leverage | ||||||
| Debt / Equity | 0.48 | 0.43 | 0.38 | 0.35 | 0.41 | 0.52 |
| Debt / Assets | 0.20 | 0.17 | 0.15 | 0.14 | 0.16 | 0.19 |
| Debt / EBITDA | 0.98 | 1.28 | 1.15 | 0.94 | 1.26 | 1.38 |
| Interest coverage | 33.6x | 60.5x | 19.5x | 78.7x | 90.1x | 82.1x |
| Equity multiplier | 2.44 | 2.52 | 2.44 | 2.44 | 2.46 | 2.76 |
| Liabilities / Assets | 0.59 | 0.60 | 0.59 | 0.59 | 0.59 | 0.64 |
| Efficiency | ||||||
| Asset turnover | 0.47 | 0.49 | 0.51 | 0.51 | 0.52 | 0.47 |
| Inventory turnover | 2.13 | 2.21 | 2.37 | 2.49 | 2.87 | 3.04 |
| Days sales outstanding | 67d | 61d | 64d | 62d | 59d | 60d |
| Days inventory outstanding | 171d | 165d | 154d | 147d | 127d | 120d |
| Days payable outstanding | 145d | 137d | 132d | 137d | 135d | 122d |
| Cash conversion cycle | 93d | 89d | 85d | 71d | 51d | 58d |
| Valuation | ||||||
| P / E | 18.8x | 25.0x | 11.4x | 26.2x | 21.9x | 28.6x |
| P / B | 6.2x | 4.9x | 5.8x | 6.1x | 6.2x | 6.6x |
| P / S | 5.3x | 4.0x | 4.7x | 5.0x | 4.9x | 5.1x |
| EV / EBITDA | 13.0x | 14.9x | 18.0x | 16.8x | 19.8x | 18.5x |
| Growth | ||||||
| Revenue growth (YoY) | 6.0% | 4.3% | -10.3% | 1.2% | 13.6% | 0.6% |
| Revenue CAGR (3y) | -0.3% | -1.8% | 1.0% | 5.0% | 7.0% | - |
| Revenue CAGR (5y) | 2.7% | 1.6% | 2.2% | - | - | - |
| Gross profit growth (YoY) | 4.2% | 4.7% | -8.2% | -0.1% | 18.0% | -0.6% |
| Operating income growth (YoY) | 95.2% | 10.8% | -30.7% | 31.7% | 0.0% | -4.8% |
| Net income growth (YoY) | 90.6% | -60.0% | 95.9% | -14.1% | 41.9% | -2.7% |
| EPS growth (YoY) | 90.5% | -57.8% | 103.9% | -13.8% | 41.7% | -2.1% |
| EPS CAGR (3y) | 17.9% | -9.5% | 35.5% | 6.1% | 11.7% | 127.2% |
| EPS CAGR (5y) | 14.9% | 0.6% | 19.6% | 70.3% | 5.7% | 0.1% |
| FCF growth (YoY) | -0.7% | 8.7% | 6.2% | -13.0% | -2.1% | 1.4% |
| FCF CAGR (5y) | -0.5% | -0.1% | -0.3% | -0.7% | 4.9% | 5.0% |
| Book value growth (YoY) | 14.1% | 3.9% | -10.5% | 3.8% | 17.0% | 6.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-28.
Business segments
$34.31B totalInnovative Medicine$25.38B · 74.0%
Med Tech$8.93B · 26.0%
Product / service
$53.68B totalDARZALEX$8.27B · 15.4%
Stelara$3.85B · 7.2%
Tremfya$3.53B · 6.6%
ELECTROPHYSIOLOGY$2.89B · 5.4%
INVEGASUSTENNAXEPLIONTRINZATREVICTA$2.73B · 5.1%
Xarelto$2.63B · 4.9%
GENERAL$2.26B · 4.2%
TRAUMA$2.06B · 3.8%
ADVANCED$1.90B · 3.5%
CONTACTLENSESOTHER$1.75B · 3.3%
SPINESPORTSOTHER$1.66B · 3.1%
OPSUMIT$1.63B · 3.0%
UPTRAVI$1.54B · 2.9%
CARVYKTI$1.49B · 2.8%
SPRAVATO$1.49B · 2.8%
Erleada$1.45B · 2.7%
Abiomed$1.39B · 2.6%
PREZISTAPREZCOBIXREZOLSTASYMTUZA$1.23B · 2.3%
Simponi Simponi Aria$1.19B · 2.2%
Remicade$1.17B · 2.2%
HIPS$1.08B · 2.0%
KNEES$924.00M · 1.7%
Shockwave Medical Inc.$897.00M · 1.7%
IMBRUVICA$892.00M · 1.7%
CAPLYTA$700.00M · 1.3%
Other$542.00M · 1.0%
RYBREVANTLAZCLUZE$534.00M · 1.0%
SURGICAL$471.00M · 0.9%
TECVAYLI$444.00M · 0.8%
TALVEY$340.00M · 0.6%
Other Oncology$214.00M · 0.4%
OTHERNEUROSCIENCE$159.00M · 0.3%
Other Cardiovascular$124.00M · 0.2%
CONCERTAMethylphenidate$82.00M · 0.2%
Other Immunology$59.00M · 0.1%
Other Pulmonary Hypertension$54.00M · 0.1%
EDURANTrilpivirine$26.00M · 0.0%
ZYTIGA$23.00M · 0.0%
Other Infectious Diseases$12.00M · 0.0%
Geographic
$65.82B totalEurope$21.54B · 32.7%
Asia Pacific Africa$14.03B · 21.3%
US$13.66B · 20.8%
Non Us$11.72B · 17.8%
Western Hemisphere Excluding US$4.88B · 7.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.99
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing JOHNSON & JOHNSON against the 5 most active filers in the same SIC group.
Dividends
$5.24/share trailing 12 months · +4.4% YoY
| Ex-date | Per share |
|---|---|
| May 26, 2026 | $1.3400 |
| Feb 24, 2026 | $1.3000 |
| Nov 25, 2025 | $1.3000 |
| Aug 26, 2025 | $1.3000 |
| May 27, 2025 | $1.3000 |
| Feb 18, 2025 | $1.2400 |
| Nov 26, 2024 | $1.2400 |
| Aug 27, 2024 | $1.2400 |
| May 20, 2024 | $1.2400 |
| Feb 16, 2024 | $1.1900 |
| Nov 20, 2023 | $1.1900 |
| Aug 25, 2023 | $1.1900 |
| May 22, 2023 | $1.1900 |
| Feb 17, 2023 | $1.1300 |
| Nov 21, 2022 | $1.1300 |
| Aug 22, 2022 | $1.1300 |
| May 23, 2022 | $1.1300 |
| Feb 18, 2022 | $1.0600 |
| Nov 22, 2021 | $1.0600 |
| Aug 23, 2021 | $1.0600 |
| May 24, 2021 | $1.0600 |
| Feb 22, 2021 | $1.0100 |
| Nov 23, 2020 | $1.0100 |
| Aug 24, 2020 | $1.0100 |